tiprankstipranks
Advertisement
Advertisement

ARGX Stock Latest News

Argenx price target raised to $1,059 from $1,007 at Evercore ISI
The FlyArgenx price target raised to $1,059 from $1,007 at Evercore ISI
8d ago
ARGX
Argenx price target raised to $1,016 from $1,013 at BofA
PremiumThe Fly
Argenx price target raised to $1,016 from $1,013 at BofA
12d ago
ARGX
Myles Minter Reiterates Buy as Vyvgart’s Expanded FDA Label and Attractive Valuation Support Continued Growth
PremiumRatings
Myles Minter Reiterates Buy as Vyvgart’s Expanded FDA Label and Attractive Valuation Support Continued Growth
12d ago
ARGX
Argenx: FDA approves label expansion for Vyvgart, Vvygart Hytrulo
PremiumThe Fly
Argenx: FDA approves label expansion for Vyvgart, Vvygart Hytrulo
14d ago
ARGX
Argenx price target lowered to $1,170 from $1,230 at Morgan Stanley
PremiumThe Fly
Argenx price target lowered to $1,170 from $1,230 at Morgan Stanley
15d ago
ARGX
Argenx price target raised to $1,135 from $1,120 at Guggenheim
PremiumThe FlyArgenx price target raised to $1,135 from $1,120 at Guggenheim
15d ago
ARGX
Argenx price target raised to $1,260 from $1,247 at Wells Fargo
Premium
The Fly
Argenx price target raised to $1,260 from $1,247 at Wells Fargo
15d ago
ARGX
Argenx price target lowered to $1,222 from $1,227 at Stifel
Premium
The Fly
Argenx price target lowered to $1,222 from $1,227 at Stifel
16d ago
ARGX
Argenx Posts 63% Q1 Sales Surge as New CEO Steers Expansion of Autoimmune Portfolio
PremiumCompany Announcements
Argenx Posts 63% Q1 Sales Surge as New CEO Steers Expansion of Autoimmune Portfolio
16d ago
6K
ARGX
Argenx Maintains Buy Rating on Vyvgart Momentum, Robust Profitability, and Expanding Late-Stage Pipeline
PremiumRatings
Argenx Maintains Buy Rating on Vyvgart Momentum, Robust Profitability, and Expanding Late-Stage Pipeline
16d ago
ARGX
Argenx Installs New CEO Karen Massey as Van Hauwermeiren Becomes Chair After AGM Approvals
PremiumCompany Announcements
Argenx Installs New CEO Karen Massey as Van Hauwermeiren Becomes Chair After AGM Approvals
16d ago
6K
ARGX
Argenx Completes First Safety Study for New Antibody ARGX-213
PremiumCompany Announcements
Argenx Completes First Safety Study for New Antibody ARGX-213
30d ago
ARGX
Argenx Showcases Broad VYVGART and Pipeline Gains at AAN 2026 to Bolster Neuromuscular Leadership
PremiumCompany AnnouncementsArgenx Showcases Broad VYVGART and Pipeline Gains at AAN 2026 to Bolster Neuromuscular Leadership
1M ago
6K
ARGX
Argenx announces Phase 3 Adapt Oculus study met primary endpoint
Premium
The Fly
Argenx announces Phase 3 Adapt Oculus study met primary endpoint
1M ago
ARGX
Argenx Completes Key CIDP Switch Study, Setting Up Next Steps for Efgartigimod
Premium
Company Announcements
Argenx Completes Key CIDP Switch Study, Setting Up Next Steps for Efgartigimod
2M ago
ARGX
Argenx price target lowered to $1,014 from $1,060 at Oppenheimer
PremiumThe Fly
Argenx price target lowered to $1,014 from $1,060 at Oppenheimer
2M ago
ARGX
Argenx added to European Conviction List at Goldman Sachs
PremiumThe Fly
Argenx added to European Conviction List at Goldman Sachs
2M ago
ARGX
Argenx Sets May 6, 2026 AGM and Unveils Board Changes as Jim Daly Retires
PremiumCompany Announcements
Argenx Sets May 6, 2026 AGM and Unveils Board Changes as Jim Daly Retires
2M ago
6K
ARGX
Argenx Files 2025 Annual Report and Links Dutch Filing to U.S. Registrations
PremiumCompany Announcements
Argenx Files 2025 Annual Report and Links Dutch Filing to U.S. Registrations
2M ago
6K
ARGX
Argenx Halts Phase 3 Thyroid Eye Disease Trial: Clinical Setback With Focused Market Impact
PremiumCompany AnnouncementsArgenx Halts Phase 3 Thyroid Eye Disease Trial: Clinical Setback With Focused Market Impact
2M ago
ARGX
Argenx Ends Phase 3 Thyroid Eye Disease Trial, Resetting Expectations for Efgartigimod
Premium
Company Announcements
Argenx Ends Phase 3 Thyroid Eye Disease Trial, Resetting Expectations for Efgartigimod
2M ago
ARGX
Argenx’s Long‑Term ITP Study Reaches Completion, Sharpening the Outlook for Efgartigimod
Premium
Company Announcements
Argenx’s Long‑Term ITP Study Reaches Completion, Sharpening the Outlook for Efgartigimod
2M ago
ARGX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >